MedPath

Evaluating Microvascular Dysfunction in Symptomatic Patients With HypertroPhic CaRdiomyopathy

Completed
Conditions
Hypertrophic Cardiomyopathy
Registration Number
NCT02994615
Lead Sponsor
Lawson Health Research Institute
Brief Summary

Patients with hypertrophic cardiomyopathy are being compared to a control group. IMR will be assessed with a pressure wire. Clinical f/u at 3 months and 6 months and a 48 hour holter monitor.

Detailed Description

Not available

Recruitment & Eligibility

Status
COMPLETED
Sex
All
Target Recruitment
19
Inclusion Criteria
  • Age 18-80
  • Already have an indication for coronary angiography
  • Previous diagnosis of hypertrophic cardiomyopathy (unless control)
Read More
Exclusion Criteria
  • Fractional flow reserve found to be significant (FFR < 0.8)
  • Already have a condition associated with or likely to be associated with an elevated IMR (diabetes, cardiac syndrome X, takotsubo cardiomyopathy, hypertensive cardiomyopathy, severe aortic stenosis, STEMI)
Read More

Study & Design

Study Type
OBSERVATIONAL
Study Design
Not specified
Primary Outcome Measures
NameTimeMethod
IMR in patients with hypertrophic cardiomyopathy (HCM) versus controls1 day
Secondary Outcome Measures
NameTimeMethod
Number of ventricular tachycardia6 months

Measured during 48 h recording after 6 months

Shortness of breath - NYHA classUp to 6 months
Chest pain - Canadian Cardiovascular Society (CCS) classUp to 6 months

Trial Locations

Locations (1)

London Health Sciences Centre

🇨🇦

London, Canada

© Copyright 2025. All Rights Reserved by MedPath